T1	Procedure 301 313	chemotherapy
T2	Procedure-Name 301 313	chemotherapy
E1	Procedure:T1 Name:T2 Temporality:E30 Minimum-Count:E31
T3	Procedure 257 274	endocrine therapy
T4	Procedure-Name 257 274	endocrine therapy
E3	Procedure:T3 Name:T4
T5	Procedure 372 389	endocrine therapy
T6	Procedure-Name 372 389	endocrine therapy
E5	Procedure:T5 Name:T6
T7	Condition 666 693	acute myocardial infarction
T8	Condition-Name 666 693	acute myocardial infarction
E7	Condition:T7 Name:T8 Severity:T78 Temporality:E16
T9	Condition 621 629	diseases
T10	Condition-Name 621 629	diseases
E9	Condition:T9 Name:T10 Severity:T76
T11	Condition 756 780	Congestive heart failure
T12	Condition-Name 756 780	Congestive heart failure
E11	Condition:T11 Name:T12
T13	Condition 831 853	ventricular arrhythmia
T14	Condition-Name 831 853	ventricular arrhythmia
E13	Condition:T13 Name:T14
T15	Procedure 873 885	intervention
T16	Procedure-Name 873 885	intervention
E15	Procedure:T15 Name:T16
T17	Eq-Operator 694 700	within
A1	Eq-Operator-Value T17 LTEQ
T18	Eq-Operator 822 823	>
A2	Eq-Operator-Value T18 GT
T19	Eq-Temporal-Unit 178 183	years
A3	Eq-Temporal-Unit-Value T19 year
T20	Eq-Temporal-Unit 703 709	months
A4	Eq-Temporal-Unit-Value T20 month
T21	Eq-Operator 439 440	-
A5	Eq-Operator-Value T21 BETWEEN
T22	Eq-Value 170 172	18
T23	Eq-Value 175 177	75
T24	Eq-Value 438 439	0
T25	Eq-Value 440 441	1
T26	Eq-Value 701 702	6
T27	Eq-Value 824 825	2
T28	Eq-Comparison 694 709	within 6 months
E16	Eq-Comparison:T28 Operator:T17 Temporal-Unit:T20 Value:T26
T29	Eq-Comparison 816 825	class > 2
E17	Eq-Comparison:T29 Operator:T18 Value:T27 Unit:T90
T30	Eq-Comparison 438 441	0-1
E18	Eq-Comparison:T30 Operator:T21 Value:T24 Value2:T25
T33	Eq-Comparison 242 256	Received prior
E21	Eq-Comparison:T33 Temporal-Period:T34
T34	Eq-Temporal-Period 242 256	Received prior
A8	Eq-Temporal-Period-Value T34 past
T35	Eq-Comparison 480 494	received prior
E22	Eq-Comparison:T35 Temporal-Period:T36
T36	Eq-Temporal-Period 480 494	received prior
A9	Eq-Temporal-Period-Value T36 past
T31	Condition 152 158	Cancer
E2	Condition:T31 Name:T32
T32	Condition-Name 152 158	Cancer
T41	Modifier 131 151	HER2 negative Breast
E4	Modifier:T41 Modifies:T32
T42	Modifier 104 129	hormone-receptor positive
E6	Modifier:T42 Modifies:T32
T43	Modifier 92 102	metastatic
E8	Modifier:T43 Modifies:T32
T44	Modifier 71 88	locally recurrent
E10	Modifier:T44 Modifies:T32
T45	Or 89 91	or
E12	Or:T45 Arg:E10 Arg2:E8
T46	Eq-Comparison 170 183	18 - 75 years
E14	Eq-Comparison:T46 Operator:T47 Value:T22 Value2:T23 Temporal-Unit:T19
T47	Eq-Operator 173 174	-
A6	Eq-Operator-Value T47 BETWEEN
T48	Age 165 168	Age
E19	Age:T48 Eq-Comparison:E14
T49	Condition 189 203	postmenopausal
E20	Condition:T49 Name:T50
T50	Condition-Name 189 203	postmenopausal
T51	Life-Stage-And-Gender 204 209	women
A7	Life-Stage-And-Gender-Type T51 female
T52	Or 210 212	or
E25	Or:T52 Arg:T51 Arg2:E26
R1	If-Then Arg1:T51 Arg2:E20	
T53	Condition 213 230	prepostmenopausal
E26	Condition:T53 Name:T54
T54	Condition-Name 213 230	prepostmenopausal
T55	Life-Stage-And-Gender 231 236	women
A12	Life-Stage-And-Gender-Type T55 female
R2	If-Then Arg1:T55 Arg2:E26	
T37	Condition 338 345	disease
E23	Condition:T37 Name:T38
T38	Condition-Name 338 345	disease
T56	Modifier 327 337	metastatic
E27	Modifier:T56 Modifies:T38
T57	Modifier 318 326	advanced
E28	Modifier:T57 Modifies:T38
T58	Or 326 327	/
E29	Or:T58 Arg:E28 Arg2:E27
R3	Treatment-For Arg1:E1 Arg2:E23	
T59	Eq-Comparison 284 292	previous
E30	Eq-Comparison:T59 Temporal-Period:T60
T60	Eq-Temporal-Period 284 292	previous
A10	Eq-Temporal-Period-Value T60 past
T61	Eq-Comparison 280 283	One
E31	Eq-Comparison:T61 Value:T62
T62	Eq-Value 280 283	One
T63	And 357 368	in addition
E32	And:T63 Arg:E1 Arg2:E5
T64	Observation 396 430	Eastern Cooperative Oncology Group
E33	Observation:T64 Name:T65
T65	Observation-Name 396 430	Eastern Cooperative Oncology Group
T66	Observation 432 436	ECOG
E34	Observation:T66 Name:T67 Stage:E18
T67	Observation-Name 432 436	ECOG
R4	Abbrev-Of Arg1:E34 Arg2:E33	
T39	Procedure 495 504	treatment
E24	Procedure:T39 Temporality:E22
T40	Drug 514 530	CDK4/6 inhibitor
E35	Drug:T40 Name:T68
T68	Drug-Name 514 530	CDK4/6 inhibitor
T69	Drug 532 542	everolimus
E36	Drug:T69 Name:T70
T70	Drug-Name 532 542	everolimus
T71	Drug 546 556	fulvestant
E37	Drug:T71 Name:T72
T72	Drug-Name 546 556	fulvestant
T73	Or 543 545	or
E38	Or:T73 Arg:E36 Arg2:E37
R5	Using Arg1:E24 Arg2:E35	
T74	Modifier 605 620	cerebrovascular
E39	Modifier:T74 Modifies:T10
T75	Modifier 586 600	cardiovascular
E40	Modifier:T75 Modifies:T10
T76	Severity 574 585	significant
A11	Severity-Value T76 severe
T77	Or 601 604	and
E41	Or:T77 Arg:E40 Arg2:E39
T78	Severity 659 665	severe
A13	Severity-Value T78 severe
R6	Example-Of Arg1:E7 Arg2:E9	
T79	Study 717 727	enrollment
E42	Study:T79 
T80	Temporal-Connection 710 716	before
E43	Temporal-Connection:T80 Arg:E16 Arg2:E42
A14	Temporal-Connection-Type-Value E43 before
T81	Condition 748 754	angina
E44	Condition:T81 Name:T82 Severity:T83 Stability:T84
T82	Condition-Name 748 754	angina
T83	Severity 741 747	severe
A15	Severity-Value T83 severe
T85	Or 738 740	or
E46	Or:T85 Arg2:T83 Arg:T84
T86	Observation 782 808	New York heart association
E47	Observation:T86 Name:T87
T87	Observation-Name 782 808	New York heart association
R7	Equivalent-To Arg1:E47 Arg2:E11	
T88	Observation 810 814	NYHA
E48	Observation:T88 Name:T89 Stage:E17
T89	Observation-Name 810 814	NYHA
R8	Abbrev-Of Arg1:E48 Arg2:E47	
T90	Eq-Unit 816 821	class
T91	Or 828 830	or
E49	Or:T91 Arg:E48 Arg2:E13
T92	Assertion 860 864	need
E50	Assertion:T92 Asserted:E15
A16	Assertion-Type-Value E50 hypothetical
R9	Treatment-For Arg1:E15 Arg2:E13	
T93	Procedure 33 47	pathologically
E51	Procedure:T93 Name:T94
T94	Procedure-Name 33 47	pathologically
R10	Found-By Arg1:E2 Arg2:E51	
A17	Observation-Type-Value T65 clinical-score
A18	Observation-Type-Value T67 clinical-score
R11	Using Arg1:E24 Arg2:E36	
R12	Using Arg1:E24 Arg2:E37	
T84	Stability 729 737	unstable
A19	Stability-Value T84 change
A20	Observation-Type-Value T87 clinical-score
A21	Observation-Type-Value T89 clinical-score
